UK markets closed

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.7700+0.1200 (+4.53%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 105.52M
Enterprise value 53.03M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.07
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.50

Trading information

Stock price history

Beta (5Y monthly) 1.71
52-week change 381.05%
S&P500 52-week change 327.86%
52-week high 34.7500
52-week low 31.4600
50-day moving average 32.9032
200-day moving average 32.9284

Share statistics

Avg vol (3-month) 341.96k
Avg vol (10-day) 360.46k
Shares outstanding 537.96M
Implied shares outstanding 638.95M
Float 823.82M
% held by insiders 126.71%
% held by institutions 122.02%
Shares short (15 Mar 2024) 4212.62k
Short ratio (15 Mar 2024) 47.18
Short % of float (15 Mar 2024) 40.62%
Short % of shares outstanding (15 Mar 2024) 40.56%
Shares short (prior month 15 Feb 2024) 4189.32k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 315 Nov 2018
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 315 Nov 2018

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-30.02%
Return on equity (ttm)-46.77%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -21.24M
Net income avi to common (ttm)-19.38M
Diluted EPS (ttm)-0.6000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)52.9M
Total cash per share (mrq)1.39
Total debt (mrq)400k
Total debt/equity (mrq)0.78%
Current ratio (mrq)19.27
Book value per share (mrq)1.35

Cash flow statement

Operating cash flow (ttm)-18.73M
Levered free cash flow (ttm)-11.45M